本文選題：GPCRomics + pancreatic��； 參考：《中國藥理學(xué)與毒理學(xué)雜志》2017年10期

【摘要】：G protein-coupled receptors(GPCRs)are the most widely targeted class for approved drugs but only a small portion(-15%)of GPCRs are currently targeted.Work in my laboratory has tested the hypothesis that individual cell types express previously unrecognized GPCRs that regulate cell function and may be novel drug targets.A key focus has been our efforts to define differential expression(DE)of GPCRs on normal cells versus cells from patients with diseases:pulmonary arterial smooth muscle cells/pulmonary arterial hypertension,lung and cardiac fibroblasts/lung and cardiac fibrosis and pancreatic cells/pancreatic ductal adenocarcinoma(PDAC).To test our hypothesis,we have used unbiased(GPCRomic)approaches(Taqman GPCR arrays and RNA-seq),mining of publicly available datasets(the GTEX database for normal tissues and the Cancer Genome Atlas,TCGA)and studies of signaling and functional activity to validate newly detected GPCRs.The GPCRomic studies reveal that most cell types and tissues express100 different GPCRs with limited prior data for many highly expressed GPCRs,numerous of which are"orphans"(which lack known physiologic agonists).Numerous GPCRs have DE and alter functionin diseased cells.For example,studies of PDAC tumors/cells and pancreatic cancer-associated fibroblasts(PCAFs)identify two GPCRs with high DE,respectively,in PDAC cells compared to normal pancreatic ductal epithelial cells and in PCAFs compared to normal pancreatic Fs/stellate cells.These two GPCRs:(1)are frequently,highly expressed in PDAC tumors compared to normal pancreas and(2)regulate functional activities that influence the malignant phenotype.Overall,the results indicate the utility of unbiased GPCRomic and data-mining approaches to identify previously unrecognized,functional GPCRs that may contribute to human disease and that may be novel,drug gable targets.
[Abstract]:G protein-coupled receptors(GPCRs)are the most widely targeted class for approved drugs but only a small portion(-15%)of GPCRs are currently targeted.Work in my laboratory has tested the hypothesis that individual cell types express previously unrecognized GPCRs that regulate cell function and may be novel drug targets.A key focus has been our efforts to define differential expression(DE)of GPCRs on normal cells versus cells from patients with diseases:pulmonary arterial smooth muscle cells/pulmonary arterial hypertension,lung and cardiac fibroblasts/lung and cardiac fibrosis and pancreatic cells/pancreatic ductal adenocarcinoma(PDAC).To test our hypothesis,we have used unbiased(GPCRomic)approaches(Taqman GPCR arrays and RNA-seq),mining of publicly available datasets(the GTEX database for normal tissues and the Cancer Genome Atlas,TCGA)and studies of signaling and functional activity to validate newly detected GPCRs.The GPCRomic studies reveal that most cell types and tissues express100 different GPCRs with limited prior data for many highly expressed GPCRs,numerous of which are"orphans"(which lack known physiologic agonists).Numerous GPCRs have DE and alter functionin diseased cells.For example,studies of PDAC tumors/cells and pancreatic cancer-associated fibroblasts(PCAFs)identify two GPCRs with high DE,respectively,in PDAC cells compared to normal pancreatic ductal epithelial cells and in PCAFs compared to normal pancreatic Fs/stellate cells.These two GPCRs:(1)are frequently,highly expressed in PDAC tumors compared to normal pancreas and(2)regulate functional activities that influence the malignant phenotype.Overall,the results indicate the utility of unbiased GPCRomic and data-mining approaches to identify previously unrecognized,functional GPCRs that may contribute to human disease and that may be novel,drug gable targets.
【作者單位】： Departments
【基金】：supported by NIH grants(R21CA202608,R21AG053568) Dept of Defense Grant(W81XWH-14-1-0372) Bristol Myers Squibb,Padres Pedal the Cause PTC2017 an ASPET-David Lehr Research Award
【分類號(hào)】：R96

【相似文獻(xiàn)】

相關(guān)期刊論文 前5條

1 韋日生;賀師鵬;;GPCRs的變構(gòu)調(diào)節(jié)劑與藥物新靶點(diǎn)[J];生理科學(xué)進(jìn)展;2012年06期

2 Dong-soon IM;;Two ligands for a GPCR,proton vs lysolipid[J];Acta Pharmacologica Sinica;2005年12期

3 Baloucoune Guillaume Antoine;肖勝杰;蔣明;皮振鈞;黃思羅;;GPCRs組成性活性的研究進(jìn)展及意義[J];現(xiàn)代生物醫(yī)學(xué)進(jìn)展;2012年19期

4 DU Bing;LIU MingYao;;Structure of the human P2Y_(12) receptor in complex with an antithrombotic drug[J];Science China(Life Sciences);2014年06期

5 阮嬪;趙菡;薛禮;蔣明;黃思羅;;C族GPCRs的半胱氨酸富集區(qū)的研究進(jìn)展及藥學(xué)意義[J];現(xiàn)代生物醫(yī)學(xué)進(jìn)展;2012年09期

相關(guān)碩士學(xué)位論文 前2條

1 惠文其;三種與神經(jīng)退行性疾病相關(guān)的GPCRs的合理藥物設(shè)計(jì)[D];第三軍醫(yī)大學(xué);2016年

2 李保坤;GPCRs配體小分子的計(jì)算機(jī)模擬與藥物設(shè)計(jì)[D];蘇州大學(xué);2013年

，

本文編號(hào)：2081600